Sky has mentioned many times: combination is the king.
To tackle all these tumor-associated immunosuppressive characteristics, combination is the way. IMO, NWBO has achieved the most crucial milestone in treating cancer: triggering massive and sustainable t cell infiltration into tumor sites. The next step is to take care of immunosuppresion of different types. Of course, adding CYT107 to increase t cell counts should be included in the future trials too.
Guess which company has most of the inhibitors can be used in future clinical trials to tackle immunosuppresion.
Market Data 
Markets 
AI
